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Abstract 
A 59-year-old male presented with a painful right inguinal swelling and deep vein thrombosis 
at the ipsilateral leg. An inguinal hernia was initially diagnosed, but during surgery a large 
mass was found anteriorly to the peritoneal sheaths. Histology revealed a high-grade 
pleomorphic rhabdomyosarcoma. The mass advanced rapidly, occupying the whole right iliac 
fossa and metastasizing to the lung. Despite first- and second-line chemotherapy, the 
patient deteriorated rapidly and died. Rhabdomyosarcomas should be managed in 
specialized centres as they have prognostic factors and histologic features still controversial 
and poorly clarified. 
 
Introduction 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, 
representing the fifth most frequent solid tumour in childhood [1]. However, it is an 
extremely rare tumour in adults, accounting for less than 1% of malignancies in this 
population [2]. 
The pleomorphic subtype of RMS is histologically diagnosed in 19% of adult cases 
and is characterized by aggressive biology and a significantly worse prognosis 
compared to the other histological subtypes [3]. Case Rep Oncol 2012;5:74–79 
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The aim of the present study is to report a very rare case of inguinal pleomorphic 
RMS and review the related literature. 
Case Report 
A 59-year-old male presented to the emergency department of our hospital with a painful hard 
swelling at the right inguinal fossa. His medical history included a mitral valve prolapse with low 
blood pressure and a 4-month history of deep vein thrombosis of the right lower leg. He also reported 
a significant weakness and a weight loss of 4 kg during the last 2 months. The laboratory tests 
revealed a mild normochromic, normocytic anaemia (Hb: 10 g/dl), slightly elevated serum calcium 
levels (10.6 mg/dl; normal value range: 8.2–10.4 mg/dl) and increased serum lactate dehydrogenase 
levels (576 U/l; normal value range: 230–460 U/l). Based on a surgical consultation, this inguinal 
mass was considered a complicated right inguinal hernia, and the patient was admitted for surgical 
management. Surprisingly, the operation revealed an inoperable mass anterior to the peritoneal 
sheaths, and a biopsy was taken for histological examination. 
The macroscopic examination reported a firm mass measuring 1.6 × 1.2 × 0.8 cm with grayish 
white cut surface. Analysis of the haematoxylin-eosin-stained sections revealed a malignant 
pleomorphic mesenchymal neoplasm, characterized mainly by proliferation of atypical spindle and 
few epithelioid cells, in a plexiform pattern, admixed with giant multinucleated cells with abundant 
eosinophilic nucleoli (fig. 1). Immunohistochemistry displayed strong and diffuse positive stains for 
smooth muscle actin, vimentin, and CD99, and focally positive nuclear and cytoplasmic stains for Myo 
D1 and myogenin (fig. 2). Some cells were positive for desmin, and 60% of the tumour cells expressed 
MDM-2 protein. Ki-67 (MIB-1) ranged from 50–60%. The combination of the above findings 
supported the diagnosis of a high-grade pleomorphic RMS. 
The tumour staging, using abdominal and chest CT scan, revealed enlarged right common iliac and 
external iliac lymph nodes, invading the right obturator internus muscle and measuring up to 8.7 cm 
in diameter, with central hypodense areas consisting of necrotic foci. A 3-cm secondary lesion was 
found at the posterior right lower pulmonary lobe. A bone scan was negative for bone involvement 
but showed marked radionuclide uptake at the periphery of the inguinal mass. The bone marrow 
biopsy was negative for bone marrow infiltration. The patient’s neoplasm was staged as group IV 
according to the International RMS Study Group (IRSG) surgical-pathologic grouping system, and as 
stage 4 according to the IRSG staging system (table 1 and table 2) [4]. 
One month after his admission, the patient was referred to the oncology department. However, his 
performance status had already deteriorated to 2 due to the rapid growth of the right pelvic mass (12 
and 19 cm in the transverse and the longitudinal diameter, respectively) causing considerable oedema 
and leg pain. The patient required strong opioid analgesics for pain relief. 
Chemotherapy was immediately administered using the VAC regimen (vincristine, actinomycin-D, 
and cyclophosphamide) in 4 cycles. Re-evaluation by CT scans revealed that the disease had further 
advanced to the lung and the pelvis, and new secondary lesions were identified in the liver. A second-
line chemotherapy was administered (ifosfamide and etoposide) in 3 cycles. However, the patient’s 
symptoms continued to deteriorate, although there was no evidence of significant toxicity from the 
treatment. The whole situation was thoroughly discussed with the patient and his family, and the 
decision was to discontinue chemotherapy and administer only symptomatic treatment. Ultimately, 
the patient passed away, 10 months following the initial diagnosis. 
Discussion 
This case represents the second inguinal pleomorphic RMS ever reported in the 
international literature [5]. RMSs are a group of different pathobiologic entities linked 
by a common characteristic: to form neoplastic skeletal muscle. This is derived from 
biological forces related to aberrant transcription signals that lead to the production of Case Rep Oncol 2012;5:74–79 
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myogenic proteins. These differing morphologic features were recognized in the mid-
1900s by Horn and Enterline, who divided RMSs into embryonal, alveolar, botryoid, 
and pleomorphic subtypes [6]. However, recent histologic and molecular studies led to 
the description of additional entities, such as spindle cell and anaplastic RMSs. 
Following further refinements of the original entities, using molecular biology, the 
International Classification of Rhabdomyosarcomas separated the histological subtypes 
according to their prognostic significance [6]. As a consequence, botryoid and spindle 
cell RMSs were assigned to the superior-prognosis group, embryonal RMSs to the 
intermediate-prognosis group, and alveolar RMSs to the poor-prognosis group. 
However, pleomorphic RMSs were not included in this classification, as they concerned 
the paediatric population in which the pleomorphic subtype is a very rare entity [3, 7]. 
Pleomorphic RMSs occur predominately in middle-aged men (median age: 54–56 
years) and are mostly located in the lower extremity. Less frequent sites of 
presentation are the abdomen, retroperitoneum, chest wall, spermatic cord/testes, 
upper extremity, mouth, and orbit [8, 9]. They typically have an aggressive clinical 
course, demonstrating an overall poor prognosis [8, 9]. 
Given the rarity of the disease and the lack of large prospective controlled studies, 
very few related data are available, deriving from studies with small numbers of 
patients. Furlong et al. [8] reported 38 pleomorphic RMS cases (28 men and 10 
women). These patients presented with a rapidly growing mass (with a median size of 
6.9 cm) involving mainly the lower extremity. The response to treatment was rather 
poor as approximately 70% of the patients died of the disease within 20 months. The 
progression-free survival of 45% of these patients was reported to be 9 months. 
Gaffney et al. [9] reported 11 pleomorphic RMS cases (10 men and 1 woman; median 
age: 56 years) with the thigh being the most common site of disease presentation. From 
the 8 cases that had clinical follow-up, 1 patient was alive 20 months after the initial 
diagnosis, whereas the remaining 7 patients had died 2–28 months following diagnosis. 
In the study by Ferrari et al. [2], localized pleomorphic RMS was found in 37 patients 
(20% of the total RMS population), and complete surgical resection was possible for 
74% of these patients (compared to 30% for other RMS histologic subtypes). Only 12 
patients received chemotherapy. Overall, the 5-year event-free survival and overall 
survival rates were 29.9 and 53.4% for the pleomorphic RMSs compared to 32.9 and 
45.7%, respectively, for the non-pleomorphic RMSs. However, these results correspond 
to the localized rather than the metastatic setting, which was the case in our patient. In 
the same study, it has been suggested that when the paediatric treatment guidelines are 
followed in adult patients, the response rates are comparable to those observed in 
children. According to the major conclusions derived from the meta-analysis of the 
Intergroup RMS Studies I–IV, VAC remains the standard regimen for patients with 
advanced disease [4]. 
The underlying aetiology of the poor prognosis in this disease is not yet well 
understood. Reports regarding prognostic and predictive factors of adult pleomorphic 
RMS patients are very few and contradictory. Little et al. [10] suggest that pleomorphic 
RMS is the most common RMS subtype in adults, accounting for 43% of the RMS 
population with locoregional disease. Pleomorphic RMSs were grouped and analyzed 
together with embryonal RMSs (a total of 63 patients) and did not show significant 
differences in terms of progression-free survival or overall survival compared to the Case Rep Oncol 2012;5:74–79 
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alveolar subtype. Nevertheless, metastasis-free survival was slightly higher for the 
pleomorphic/embryonal group (58 vs. 32% for the alveolar group, p = 0.04). In another 
study, Joshi et al. [11] reported that increasing age is a negative prognostic factor 
among children with RMSs. 
On the other hand, a retrospective analysis from the Surveillance, Epidemiology and 
End Results database of 205 adults and 17 children with pleomorphic RMSs, which was 
recently published by Sultan et al. [3], concluded that adult patients with pleomorphic 
RMSs demonstrate a worse prognosis, and that this is irrespective of the site of origin 
of the tumour or the histological subtype. It is noteworthy that there were 
exceptionally few children with pleomorphic RMSs in this database, and that these had 
a risk to die twice as high as adults (HR 3.73 vs.1.79, p < 0.001). 
Conclusion 
In accordance with previous studies, our patient had a pleomorphic RMS with highly 
malignant features, progressing very quickly and not responding to aggressive 
chemotherapy. These findings further support our previous suggestion that these 
patients should be managed in specialized centres in order to receive optimal 
treatment and participate in large, well-designed, prospective trials to analyze 
prognostic factors and histological features that are still controversial. 
 
 
 
Table 1. According to the IRSG, RMSs are classified into 4 post-surgical pathologic groups, depending 
on the extent of the residual disease after initial surgical treatment 
        Group  Definition 
        I  Localized tumour, completely removed with pathologically 
clear margins and no regional lymph node involvement 
        II  Localized tumour, grossly removed with (a) microscopically 
involved margins, (b) involved, grossly resected regional 
lymph nodes 
        III  Localized tumour, with gross residual disease after grossly 
incomplete removal, or biopsy only 
        IV  Distant metastases present at diagnosis 
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Table 2. The pre-clinical IRSG staging system was adopted during the fourth IRS (1991–1997) and 
classifies patients according to the site of tumour origin, size, regional nodal involvement and 
presence or absence of metastatic disease 
                    Stage  Site of primary tumour  Tumour size  
cm 
Regional  
lymph nodes 
Distant 
metastases 
                    1  Orbit, 
non-parameningeal head and neck, 
GU non-bladder/prostate, 
biliary tract 
 
Any size 
 
N0, N1 
 
M0 
                    2  All other sites  ≤5  N0  M0 
                    3  All other sites  ≤5; 
>5 
N1; 
N0, N1 
M0 
                    4  Any site  Any size  N0, N1  M1 
                     
 
 
 
 
Fig. 1. Malignant mesenchymal neoplasm with atypical spindle and epithelioid cells; a large number 
of them present with abundant eosinophilic nucleoli. Haematoxylin-eosin stain. ×400. 
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Fig. 2. Positive nuclear and cytoplasmic stain for myogenin in neoplasmatic cells. ×400. 
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